Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Breast Cancer Research

Table 4 Results of multivariate regression analysis including Mammostrat^® risk score

	ER-positive, node-negative, tamoxifen only^a	ER-positive, tamoxifen only^a	All ER-positive cases	All Eligible cases
Relapse-free survival
Nodal status	*	5.4 × 10^-8	0.0001	2.8 × 10^-9
Grade	NS	0.046	NS	NS
Size	NS	0.010	7.0 × 10^-5	0.0007
Multifocality	0.037	0.001	0.0004	0.0004
Menopausal status	0.031	0.013	0.048	NS
Age	NS	NS	NS	NS
HER2	0.012	0.0005	0.003	0.001
PgR	NS	NS	0.079	NS
ER	*	*	*	NS
Mammostrat^®	0.076	0.064	0.025	0.0007
Distant recurrence-free survival
Nodal status	*	3.7 × 10^-7	5.1 × 10^-5	4.6 × 10^-9
Grade	NS	0.067	NS	NS
Size		0.091	0.0004	0.002
Multifocality	NS	NS	0.030	0.082
Menopausal status	NS	NS	NS	NS
Age	NS	NS	NS	NS
HER2	0.092	0.01	0.021	0.024
PgR	NS	NS	NS	NS
ER	*	*	*	NS
Mammostrat^®	0.059	0.012	0.005	6.6x10-5
Overall survival
Nodal status	*	2.5 × 10^-6	6.9 × 10^-5	9.1 × 10^-9
Grade	NS	0.074	0.036	0.088
Size		0.018	0.00021	0.011
Multifocality	NS	NS	0.061	NS
Menopausal status	NS	NS	NS	NS
Age	NS	0.080	0.037	0.017
HER2	NS	NS	NS	NS
PgR	NS	0.059	0.085	NS
ER	*	*	*	0.001
Mammostrat^®	NS	NS	0.0023	0.005

Data represent P value for significance of individual factors in multivariate analyses. ER, estrogen receptor; NS, not significant. Nodal status, node-positive versus node-negative; grade, grade 1, grade 2 or grade 3; size, < 2 cm vs. ≥ 2 cm; multifocality, presence or absence of multifocal disease; menopausal status, premenopausal versus postmenopausal; age, < 55 years versus ≥ 55 years; HER2, HER2-positive versus HER2-negative; PgR (progesterone receptor) and ER, hormone receptor-positive versus hormone receptor-negative; Mammostrat^®, risk category low, medium or high. ^aTamoxifen only, patients treated with adjuvant tamoxifen without adjuvant chemotherapy. * = not relevant as no stratification, e.g. nodal status in node negative patients.

ISSN: 1465-542X